国健清科生物医药科技

Beijing Guojian Qingke Biological Medicine Technology is a specialized biotechnology firm headquartered in Beijing, China, dedicated to the advancement of innovative cell-based immunotherapies. The company focuses on the development of Chimeric Antigen Receptor T-cell (CAR-T) and T-cell Receptor (TCR-T) therapies specifically designed to treat solid tumors, which remain a significant challenge for conventional cell therapies. By engineering immune cells to better penetrate and survive within the immunosuppressive tumor microenvironment, Guojian Qingke seeks to provide potent new options for patients with refractory cancers. Their research emphasizes overcoming the physical and immunological barriers that typically limit the efficacy of cell therapies in solid malignancies. The company is strategically located in the Beijing Bio-medicine Industry Base to leverage regional R&D resources.